Recursion Pharmaceuticals, Inc. RXRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $66.41M+11.1% | $74.68M+26.9% | $43.69M-33.0% | $64.6M+30.1% | $59.79M+29.3% | ||
| $61.61M+10.2% | $70.95M+56.8% | $69.47M+64.1% | $66.86M+62.6% | $55.9M+35.3% | ||
| $4.8M— | $3.73M— | —— | —— | —— | ||
| 7.2%— | 5%— | —— | —— | —— | ||
| $433.53M+15.1% | $475.27M+51.2% | $477.67M+67.3% | $431.2M+53.5% | $376.5M+43.6% | ||
| $156.53M-22.3% | $176.59M-0.9% | $220.12M+67.4% | $216.25M+76.0% | $201.43M+68.8% | ||
| $651.68M+2.8% | $722.81M+34.4% | $767.25M+67.0% | $714.31M+60.5% | $633.82M+49.9% | ||
| -$585.27M-2.0% | -$648.13M-35.3% | -$723.57M-83.6% | -$649.72M-64.3% | -$574.03M-52.5% | ||
| -881.3%+78.8pp | -867.9%-53.8pp | -1,656.2%-1,051pp | -1,005.8%-209pp | -960.1%-146pp | ||
| $20.91M+1,774% | $3.24M-77.2% | $7.87M-29.8% | $601K-96.0% | -$1.25M-107% | ||
| -$564.36M+1.9% | -$644.89M-38.7% | -$715.69M-86.9% | -$649.12M-70.7% | -$575.28M-60.3% | ||
| —— | —— | -$155K+97.0% | $9K+100% | -$514K+89.4% | ||
| -$559.78M+2.6% | -$644.76M-39.1% | -$715.54M-89.4% | -$649.13M-73.1% | -$574.78M-62.3% | ||
| -842.9%+118pp | -863.4%-75.3pp | -1,637.8%-1,058pp | -1,004.9%-250pp | -961.3%-195pp | ||
| -$1.16+35.9% | -$1.44+15.3% | -$1.84-18.7% | -$1.82-11.0% | -$1.81-11.7% | ||
| -$1.16+35.9% | -$1.44+15.3% | -$1.84-18.7% | -$1.82-11.0% | -$1.81-11.7% | ||
| 1.8B+53.2% | 1.7B+65.7% | 1.5B+59.1% | 1.4B+52.9% | 1.2B+39.8% | ||
| 1.8B+53.2% | 1.7B+65.7% | 1.5B+59.1% | 1.4B+52.9% | 1.2B+39.8% | ||
| $66.41M+11.1% | $74.68M+26.9% | $43.69M-33.0% | $64.6M+30.1% | $59.79M+29.3% | ||
| -$585.27M-2.0% | -$648.13M-35.3% | -$723.57M-83.6% | -$649.72M-64.3% | -$574.03M-52.5% | ||
| -$501.23M+4.6% | -$564.43M-27.6% | -$646.39M-78.0% | -$586.39M-61.1% | -$525.59M-50.8% | ||
| -$501.23M+4.6% | -$564.43M-27.6% | -$646.39M-78.0% | -$586.39M-61.1% | -$525.59M-50.8% | ||
| -754.8%+124pp | -755.8%-3.7pp | -1,479.5%-923pp | -907.8%-175pp | -879.1%-125pp | ||
| -$585.27M-2.0% | -$648.13M-35.3% | -$723.57M-83.6% | -$649.72M-64.3% | -$574.03M-52.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) generated $66.4M in revenue over the trailing twelve months, up 11.1% year over year.
- Is Recursion Pharmaceuticals, Inc. profitable?
- Recursion Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $559.8M over the trailing twelve months, a -842.9% net margin.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 7.2% and operating margin is -881.3%, with a -842.9% net margin.
- What is Recursion Pharmaceuticals, Inc.'s earnings per share?
- Recursion Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.16.
- Where does Recursion Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
